Loading
A phase 3 trial testing HS-20089 in ovarian cancer, now recruiting.
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer is a phase 3 interventional study registered as NCT06855069, led by Hansoh BioMedical R&D, and recruiting on the registry. Official title: A Multi-centre, Randomised, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer. Planned enrolment is 468 participants (estimated). The study started in 2025-03-13 and primary completion is expected in 2027-03-07. No results have been posted on ClinicalTrials.gov.
Shares HS-20089, Hansoh Pharmaceutical, Ovarian cancer.